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Thromboxane A 2 is a potent mediator of inflammation and platelet aggregation exerting its effects through the activation of a G protein-coupled receptor (GPCR), termed TP. Although the existence of dimers/oligomers in Class A GPCRs is widely accepted, their functional significance still remains controversial. Recently, we have shown that TPa and TPb homo-/hetero-dimers interact through an interface of residues in transmembrane domain 1 (TM1) whose disruption impairs dimer formation. Here, biochemical and pharmacological characterization of this dimer deficient mutant (DDM) in living cells indicates a significant impairment in its response to agonists. Interestingly, two single loss-of-function TPa variants, namely W29C and N42S recently identified in two heterozygous patients affected by bleeding disorders, match some of the residues mutated in our DDM. These two naturally occurring variants display a reduced potency to TP agonists and are characterized by impaired dimer formation in transfected HEK-293T cells. These findings provide proofs that lack of homo-dimer formation is a crucial process for reduced TPa function in vivo, and might represent one molecular mechanism through which platelet TPa receptor dysfunction affects the patient(s) carrying these mutations.
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Introduction
The completion of the human genome project identified 7 transmembrane receptors, commonly referred to as G proteincoupled receptors (GPCRs), as the widest gene family [1] . Among the five different subfamilies, the Class A or rhodopsin-like GPCRs, to which the thromboxane A 2 receptor (TP) belongs, is the largest [2] . Members of this receptor family exert a wide variety of physiological processes with alterations in GPCR function contributing to the development of a number of pathological processes. Consequently, more than 30% of the current marketed drugs target GPCRs [3] , with ongoing efforts to identify new molecules targeting the function of these proteins.
Membrane receptors from other families have long been known to form multimeric complexes, including members of the growth factor receptor family [4] . Conversely, for a long time GPCRs were considered to function as monomeric entities with their activation resulting from the stoichiometric binding of one receptor moiety to a single heterotrimeric G protein. Indeed, a number of biochemical and biophysical data are consistent with the ability of rhodopsin [5] [6] [7] , or other GPCRs [8] [9] [10] to activate their cognate G proteins in a monomeric form. However, pharmacological data from various GPCRs are not compatible with such a model, and increasing evidence suggests that these receptors exist and function as oligomeric complexes of two or more protomers [11] . Although controversial until a few years ago, the formation of GPCR dimers/oligomers has now been demonstrated not only in ectopically transfected cells, but also in native tissues in vivo and even through the resolution of crystallized receptor structures [12] . In spite of these evidence and of the undisputed role of dimerization for Class C GPCRs [13, 14] , the significance of dimerization remains controversial for the other classes of GPCRs [15, 16] .
Thromboxane A 2 (TxA 2 ), a product of the oxidative metabolism of arachidonic acid, is a potent mediator of inflammation, a stimulator of platelet activation and aggregation, and a constrictor and mediator of proliferation of vascular and airway smooth muscle cells [17, 18] . In humans, the TP receptor is coded from a single gene that undergoes alternative splicing. This gives rise to two isoforms, termed TPa (343 residues) and TPb (407 residues) which share identical N-terminal 328 amino acids and different Cterminal tails of 15 and 79 aminoacids, respectively [19] . The two isoforms primarily activate Gq/11 and G12/13 heterotrimeric G proteins, although coupling to Gs, Gi, and Gh has also been reported [19] .
The TxA 2 /TP system exerts a key role in the cardiovascular system by triggering thrombus formation [20] . This has been well demonstrated through the identification of a number of patients suffering from hemostatic defects with impaired TP receptor function due to single amino acid substitutions [21] [22] [23] [24] . TP function appears to be tightly regulated, with suggestions that the deleterious cardiovascular effects of TPa could be limited by heterodimerization with either the TPb [25, 26] or prostacyclin IP receptor [27, 28] , which have been shown to regulate TPa trafficking and G protein coupling.
Different artificial systems, such as solubilization in detergents [5, 9, 29] , purification and refolding in detergent/lipid mixed micelles [10] , or incorporation into phospholipid bilayer [6, 7] , have been used to isolate GPCR monomers thus allowing the characterization of receptor monomer versus dimer pharmacology. Here, we directly compare in living cells the pharmacology and signaling of the homo-dimeric and monomeric forms of a Class A GPCR.
Recently, we have shown that TPa and TPb homo-/heterodimers are characterized by contacts between hydrophobic residues in transmembrane domain 1 (TM1) of both protomers [26] . Indeed, TM1 and TM4/5 dimers, which appear more frequently in the crystals, are the most plausible dimeric models [30] . The disruption of this interface by alanine replacement of eight amino acids ( Fig. 1 ) facing outward in dimerization-deficient mutants (DDMs) of one of the two TP isoforms is sufficient to drastically impair TPa-TPb hetero-dimerization and to significantly interfere with agonist-induced TPa endocytosis. Here, we demonstrate that a panel of pharmacodynamically distinct agonists show reduced potencies, but similar efficacies in the activation of the DDM with respect to wild type (WT) TPa homo-dimer. In addition, these agonists maintained identical binding affinities for both DDM and WT receptors, suggesting a similar active receptor conformation.
Strikingly, we also show here that two single naturally occurring mutations in TM1, W29C and N42S, that either match or are in close proximity to two of the residues mutated in our DDM (W29 and L43, respectively), display a reduced potency to agonists accompanied by an impaired dimer formation both in ectopically transfected HEK-293T cells and, at least partially, in platelet membranes from patients. These naturally occurring mutations are associated in vitro with reduced TP receptor-stimulated platelet activation and in vivo bleeding disorders [23, 24] . Overall, these data suggest the impairment of TP dimerization as one possible molecular mechanism leading to reduced platelet aggregation and secretion in response to TP activators in vivo thereby affecting patients carrying these mutations.
Materials and methods

Reagents
Cell-culture media and supplements, animal serum, antibiotics, Lipofectamine Ò 2000, Opti-MEM I and molecular biology reagents were purchased from Invitrogen (Carlsbad, CA 
DNA constructs
The generation of human TPa receptor WT, DDM, and W29C DNA constructs was described elsewhere [23, 26, 31] . TPtrunc was obtained using the site direct mutagenesis kit (statagene) following manufacturer's instructions. Briefly TPtrunc was obtained by the insertion of a stop codon at the Ser57 of receptor sequence (Ser57-Stop) using specific primers carrying the Ser57-Stop mutation (FW: 5 0 -GCGCGGCAGGGTGGTTAGCACACGCGCTCCTCC-3 0 ; RW: 5 0 -GGAGGAGCGCGTGTGCTAACCACCCTGCCGCGC-3 0 ). Mutated constructs were checked by Sanger analysis.
The cDNA encoding for the Gaq and Gb1 was purchased from Missouri S&T cDNA Research Center (Rolla, MO, USA), while the cDNA encoding for GFP 10 -Gc 2 and Ga q -Rluc8 are as in Busnelli et al., [32] and have been previously characterized in Sauliere et al. [33] . Ultrapure plasmids for cell transfection were obtained using the QIAfilter Plasmid Kits (Qiagen, Hilden, Germany).
Cell culture and transient transfections
HEK293T host cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were routinely grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin and 20 mM HEPES buffer pH 7.4, at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . For transfection, cells (5th-20th passage) were seeded onto tissue culture dishes previously coated with 5 lg/ml poly-D-lysine, and transfected at 30-40% confluence with an optimized 2:1 Lipofectamine 2000/DNA ratio as described previously [34] . All assays were performed 48 h after transfection. In co-transfection experiments with TP and Gaq, plasmids were added in a 1:5 lg ratio, respectively.
Western immunoblotting
Transfected cells were lysed in lysis buffer containing a protease inhibitor cocktail (Sigma-Aldrich). Equal amounts of proteins were resolved on SDS-PAGE (10% acrylamide) and electro-transferred to Hybond-P membrane (GE Healthcare-Amersham, Piscataway, NJ). Blots were incubated overnight at 4°C in TBST [10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1% (v/v) Tween 20] containing 5% (w/v) skimmed milk. After washing with TBST, membranes were incubated at 25°C for 2 h with anti-Myc antibody diluted in TBST-milk (Pierce, Rockford, IL). After washing in TBST, membranes were probed for 1.5 h at 25°C with horseradish peroxidaseconjugated goat anti-rabbit/mouse IgGs diluted in TBST-milk. Proteins were detected by chemiluminescence using the SuperSignal West Dura Extended Duration Substrate (Pierce) and visualized with Kodak Image Station 440 CF (Eastman Kodak Co., New Haven, CT). Band intensities were measured with the 'gel analyzer' ImageJ Ò plugin.
Platelets were probed using Abcam ab85544 a rabbit polyclonal antibody against the carboxyl-terminal of the human TP receptor as previously described [23] .
Radioligand binding and total inositol phosphate assays
Ligand binding characteristics were determined on confluent adherent cells performing a mixed-type protocol [35] with the specific receptor antagonist [ 3 H]SQ29,548 (48 Ci/mmol) as previously described [31, 34, 36] . Briefly, heterologous competition studies involved concentrations of the indicated unlabeled ligands ranging from 0.1 nM to 30 lM and 1 nM of the labeled [ 3 H] SQ29,548. After 30 min incubation at 25°C, reactions were stopped by medium aspiration, and cells were washed with ice-cold PBS containing 0.2% (w/v) BSA and lysed in 0.5 N NaOH. Radioactivity was measured by liquid scintillation counting. Binding data were analyzed as described in Data and Statistical Analysis. Quantitation of the total labeled IP accumulation was performed using a conventional gravity flow column chromatography, as described previously [31, 34, 36] . Briefly, on day before assay, cells were labeled with 0.5 lCi [myo-2- After medium removal, cells were lysed with 10 mM formic acid and lysates applied onto an anion exchange AG 1X-8 column, formate form, 200-400 mesh. The total IP fraction was then eluted with 2 M ammonium formate/formic acid buffer at pH 5 and radioactivity determined by liquid scintillation counting.
Acceptor photobleaching fluorescence Resonance energy transfer (FRET)
FRET measurements were performed with the laser-induced acceptor bleaching method previously reported [26, 37] . This type of analysis employing antibodies on living cells instead of fused fluorescent reporters to label the FRET pair offers the unique advantage over conventional FRET of only assaying surface receptors. Briefly, following in vivo exposure with anti-tag antibodies, cells were fixed in 4% (w/v) p-formaldehyde, and stained with Alexa Fluor 488-(donor fluorochrome) or 555 (acceptor fluorochrome)-conjugated secondary antibodies. Three images were captured before bleaching in the 488 and 555 nm channels using the line-by-line sequential mode without any averaging steps to reduce basal bleaching. Bleaching of the acceptor was performed within a region of interest (ROI) using 30 pulses of the 555 nm laser line at 100% intensity (each pulse 1.28 ls/pixel). After bleaching seven images were acquired in the same channels to obtain a full curve for analysis. The number of bleaching steps was held constant throughout each experiment. FRET was quantified by measuring the average intensities of ROIs in the donor and acceptor fluorochrome channels before and after bleaching using the ImageJ software (http://rsbweb.nih.gov/ij/). To determine any change of fluorescence intensities not due to FRET occurring during the measurements, a distinct membrane 'sentinel' ROI of approximately the same size of the bleached ROI was measured in parallel, and all the results were normalized according to the background bleaching recorded in this sentinel ROI. Proper controls were performed to verify that no artifacts were generated in the emission spectra throughout the experimental setup due to sample overheating. Forty measurements from four different transfections were performed for each experimental condition. 
Bioluminescent resonance energy transfer (BRET)
For
Data and statistical analysis
All results are presented as means ± S.E. When indicated, ANOVA followed by post hoc test for multiple comparisons was performed. Data from radioligand binding were evaluated by a nonlinear, least-squares curve-fitting procedure using GraphPad Prism version 5, implemented with the n-ligand m-binding site model, as described in the LIGAND computer program [38] . Concentration-response curves were evaluated using Prism 5, that uses the four-parameter logistic model as described in the ALLFIT program [39] . Parameter errors are all expressed as percentage coefficients of variation (%CV) and calculated by simultaneous analysis of at least three independent experiments performed in duplicate or triplicate. All parameter comparisons have been performed based on the F test for extra sum of square as implemented in GraphPad Prism. All curves shown are generated by computer fitting.
Results
Antagonist binding and receptor expression
To allow a proper comparison of receptor responses, transfection conditions were adjusted to ensure comparable levels of ectopic expression of WT and DDM (I25A, W29A, C35A, V36A, L39A, L43A, L44A, S47A mutant) of human TPa receptors in HEK293T cells in a range between 0.8 and 1.3 pmol/mg protein ( Table 1) . As expected, mock transfected cells showed no detectable binding to [ 3 H]-SQ29,548 (data not shown), whereas analysis of binding curves of cells transiently transfected with WT TPa displayed a monophasic behavior corresponding to a single-site model by computer modeling ( Fig. 2A) , with binding parameters as previously reported [31, 34, 36] . Of notice, the TPa DDM displayed a binding affinity not statistically different from the corresponding WT receptor (Table 1) . These results strongly indicate that DDM, is trafficked to the cell surface (Fig. 2B ), can be expressed at physiological relevant levels [40] and exhibits an overall conformation and folding not significantly different from that of WT.
Effect of TM1 mutations on homo-dimerization of TPa receptor
We previously reported that WT TPa and TPb form heterodimers through contacts between hydrophobic residues of TM1 with mutations in the TM1 stretch impairing TPa-TPb association regardless of which TP member of the co-transfected pair contains the mutated residues [26] . To confirm that the TPa DDM is impaired also in homo-dimer formation, we co-expressed WT and DDM mutant TPa tagged with an N-terminal myc epitope in HEK293T cells. Western blotting revealed distinct bands migrating on SDS-PAGE at the relative molecular masses (Mr) predicted [25] for monomeric and dimeric receptors for WT transfectants (Fig. 3A) . Interestingly, unlike the WT most of the DDM exists as a monomer. There was a significant reduction of the density of the dimeric band in DDM accompanied by increased intensity of monomeric bands referred to as glycosylated and nonglycosylated TP monomers as previously reported [25] (p < 0.001, Fig. 3B) .
To obtain direct evidence that mutations in the TM1 interface of DDM impair TPa dimerization, we performed FRET analysis using the laser-induced acceptor photobleaching method [37] . In this type of analysis fluorescence emission by a donor fluorochrome is quenched due to direct transfer of excitation energy to an acceptor fluorochrome. Upon laser-induced acceptor bleaching, this FRET is blunted and the donor signal is de-quenched. Accordingly, HEK293T cells co-transfected with different TPa pairs, tagged with HA and cmyc epitopes, were in vivo labeled with their corresponding anti-tag antibodies, fixed, subjected to indirect immunofluorescence and then imaged by laser scanning confocal microscopy. Fig. 3C demonstrates our approach. Note that an increase of fluorescence signal emitted by the donor fluorochrome resulting from de-quenching (i.e. FRET efficiency) is only present in analyzed cells co-expressing the WT TPa pair (Fig. 3D) , suggesting that only in these cells energy transfer is possible and thus dimer formation occurs. On the contrary, no increase in signal emitted by the donor fluorochrome is present in the DDM expressing cells, suggesting that mutations in TM1 are sufficient to prevent energy transfer from donor to acceptor, and thus to impair homo-dimerization of TPa.
To further characterize this phenomenon we repeated the experiments by transfecting cells with different levels of the TPa DNA (500, 5 and 0.5 ng) (Fig. 3D) . Even at the highest levels of DDM receptor expression we could still not detect any interaction between receptor monomers although we could clearly visualize both tagged versions of the receptor at the cell surface (Fig. 2B) . These results suggest that homo-dimerization of TPa within a large range of expression levels, including physiological ones (corresponding to the intermediate level [40] , is strongly destabilized in the receptor bearing TM1 mutations.
Basal activity of DDM receptor in the presence of overexpression of Gaq
A key feature of the TP receptor is a lack of constitutive activity (CA), even following increased expression of receptor, Gaq, or a combination of both [31, 36] . To further assess the pharmacological characteristics of the DDM receptor, its basal activity was compared with that of the WT by assaying total IP production in the absence of agonist stimulation (Fig. 4) . These experiments were also repeated in the presence of Gaq overexpression to try and promote CA at these receptors. In the mock condition, a 5-fold overexpression of Gaq induced an increase of total IP production (about 50% compared to no Gaq, Fig. 4) , likely due to a general increase in this G protein as previously reported [36] . Co-expression of either the WT or DDM failed to further enhance total IP production. These results demonstrate that the DDM, like the WT and other TP receptor mutants tested thus far, does not show any appreciable CA [31, 34, 36] .
Pharmacological characterization of the DDM functional activity
To fully characterize DDM activity, IP accumulation was evaluated in HEK293T cells transiently expressing WT or DDM in response to a series of pharmacodynamically different TP agonists, including the full agonists U46619 and I-BOP and the partial agonists 8-iso-PGF 2 a and 8-isoPGE 2 (Fig. 5A, B) . Computer-assisted analysis of concentration-response curves showed that EC 50 values for the different agonists at DDM were significantly shifted rightward as compared to WT (p < 0.01; Table 2 ). 8-iso-PGF 2 a and 8-isoPGE 2 activated the DDM and the WT with equal efficacies, in accordance with their pharmacodynamic profiles as partial agonists (Fig. 5A, B) .
We also assessed the ability of the TP receptor antagonist SQ29,548 and the structurally unrelated TP and DP 2 antagonist ramatroban, to inhibit agonist (U46619, 1 lM)-induced IP production by WT and DDM receptors (Fig. 5C, D) . Both antagonist Data are expressed as fold increase over basal. Curves are computer-generated from the simultaneous analysis of at least three independent experiments each performed in duplicates or triplicates. Error bars represent the means ± SE. Values for EC 50 0 s and significant differences from WT are shown in Table 2 .
inhibition curves at the DDM were significantly (p < 0.01) leftward shifted with IC 50 values around 5-6-fold lower than the WT (WT: IC 50 = 254 nM ± 66 %CV and 144 ± 29 %CV for SQ29,548 and ramatroban, respectively; DDM: 45 nM ± 61 %CV and 29 ± 56 %CV for SQ29,548 and ramatroban, respectively). This apparent increase in antagonist potencies is likely a consequence the reduced potency of U46619 to activate DDM. Collectively, these data indicate that the DDM form of TPa less efficiently responds to agonist activation across a panel of compounds endowed with different intrinsic activities than the WT homo-dimeric form.
To confirm that the pharmacological profile of our artificial DDM is not due exclusively to the presence of the eight mutations in TM1, we co-transfected the WT TP receptor with a truncated form of TP coding only for the N terminal and TM1 regions (TPtrunc), an approach previously shown to destabilize the quaternary structure and the interaction interfaces of rhodopsin [41] . While TPtrunc alone was pharmacologically silent, cotransfection with the WT TP receptor reduced receptor function (Fig. 6A) . Careful analysis of dose-response curves revealed that WT TP receptor plus TPtrunc produced a receptor profile similar to DDM with potencies (EC 50 = 84.8 nM ± 50 %CV and 111 nM ± 72 %CV, respectively) and efficacies not statistically different. Notably, TPtrunc is expressed at cellular surface and laserinduced acceptor bleaching FRET demonstrated that it is able to dimerize with WT TP receptor (Fig. 6B) . Thus, we can assume that the presence of an excess (1:10) of TPtrunc interferes with the WT-WT TP dimer formation, forcing WT TP receptor into a monomeric form. This, in turn, suggests that the pharmacological profile observed for the DDM might indeed be due to its monomeric state and not to merely the presence of mutations. It is likely that TPtrunc interferes with the quaternary structure of the homodimer, but do not necessarily block dimerization completely.
Transfection of a mutated form of the TPtrunc (carrying the same eight mutations as the DDM, TPtrunc TM1) with the WT TP receptor (Fig. 6A ) resulted in concentration response curve identical to that of WT TP alone (EC 50 = 23.2 nM ± 27 %CV and 35.6 nM ± 31 %CV, respectively) demonstrating the specificity of the functional interference exerted by the truncated form of the receptor on TP dimers/oligomers and the importance of these eight amino acids in TM1 to WT TP receptor interaction.
Ligand binding profile of the DDM receptor
The ligand binding capacities of the WT and DDM receptors transiently expressed in HEK-293T cells were also tested to assess whether the ligand binding pocket and/or the active receptor conformation was affected by mutations. Heterologous competition curves performed with [ 3 H]-SQ29,548 and several unlabeled agonists revealed unchanged affinities between both WT and DDM receptor constructs and an entire panel of compounds, including the two partial agonists 8-iso-PGF 2 a and 8-isoPGE 2 (Fig. 7A, B and Table 3 ). In addition to SQ29,548 (Table 1) , also the structurally unrelated TP antagonist, PTA2 ( Fig. 7C and D) did not show any difference in binding affinities between receptors (K i = 3.6 -lM ± 68 %CV and K i = 2.4 lM ± 67 %CV for WT and DDM, respectively). These data, therefore, are consistent with similar agonistinduced receptor conformations and G protein coupling for both WT and DDM, suggesting that the difference in signaling efficiency might be due to a difference in G protein activation, rather than to a difference in receptor conformational states.
3.6. Impact of W29C and N42S mutations on dimerization and pharmacology of TPa receptor 3.6.1. Impact in human platelets As mentioned above a patient heterozygous for the TP receptor variant W29C with impaired platelet response to TP receptor agonists has been previously identified [23] . In this study in HEK293T U46619 was demonstrated to be less potent at the W29C variant versus WT in inducing a rise of cytosolic free Ca 2+ , although the molecular mechanisms underlying this difference were not fully elucidated [23] . Importantly W29 is one of the eight residues mutated in our DDM [26] (Fig. 1) . In order to study the impact of the single W29C mutation on dimerization of TP receptor, the endogenously expressed receptor in platelets was detected with an antibody directed against the carboxyl-terminal of human TPa receptor. The TP receptor can be found in monomeric, dimeric and higher oligomeric forms in human platelets from healthy donors (Fig. 8A, HD) [25] . Platelets from the W29C patient show only a modest reduction of the dimeric TP form (Fig. 8A, W29C) , although quantification over multiple experiments seems to T) . Non-specific binding was calculated by computer as one of the unknown parameters of the model and was always <10% of total binding. Curves are computer generated from the simultaneous analysis of at least three independent mixedtype and heterologous competition experiments, each in duplicate. Values for K i 's are shown in Table 3 . suggest a decrease of both dimeric and oligomeric forms of receptor (Fig. 8B ) that, however, did not reach statistical significance. These results were not totally unexpected, considering that the patient is heterozygous for the W29C mutation [23] , and therefore is still able to express a substantial amount of dimeric WT TP.
Impact in transfected HEK293T
To further investigate the functional significance of the W29C mutation, we again used laser-induced acceptor bleaching FRET methodology outlined above on transfected HEK 293T cells. Intriguingly, there was no recovery of donor fluorescence due to a lack of energy transfer in cells overexpressing the WT-W29C pair (103% ± 0.8 SE, Fig. 9A and B) , suggesting minimal proximity and hence less dimerization between donor/acceptor proteins. Similar data were also obtained when we tested another naturally occurring mutation, N42S [24] with minimal evident energy transfer in our FRET studies (Fig 9B) . It should be noted that this residue is just one position upstream of the L43 and L44 residues mutated in our DDM (Fig. 1) . Indeed, we do not have a crystal structure of our receptor, but only a homology model [26] , and thus this slight difference might be explained by a possible dissimilarity between our model and the real TP structure. Collectively, these results strongly suggest that TPa dimerization is impaired with W29C or the N42S receptor variant, in striking agreement with the behavior of our artificial DDM.
Impact on pharmacology
We therefore further investigated the pharmacological profile of the W29C natural variant in functional assays (Fig. 10) .
Concentration-response curves of all agonists for W29C were significantly shifted rightward as compared to WT, with calculated potencies (EC 50 = 150 nM ± 21 %CV and 75 ± 9 %CV for U46619 and I-BOP, Panel A; EC 50 = 1896 nM ± 37 %CV and 43,280 ± 56 %CV for 8-iso-PGE 2 and 8-isoPGF 2a , Panel B) consistent with those of the artificial DDM (Table 2) . Interestingly, the pharmacological profile of the naturally occurring W29C mutant exactly matches that of the artificial DDM. Additionally, 8-iso-PGF 2a and 8-isoPGE 2 also confirmed their pharmacodynamic profile as partial agonists activating the W29C variant with equal efficacies (Emax = 3.2 ± 5 %CV and 3.6 ± 16 %CV, respectively). The antagonists SQ29,548 and ramatroban specifically inhibited U46619-induced total IP production by W29C with results not statistically different from DDM (data not shown).
Direct G protein activation
To further support our hypothesis that the differences in signaling efficiencies might be due to a difference in G protein activation and not a difference in receptor conformational states, we performed a direct measure of G protein activation using an intramolecular BRET 2 -based biosensor [42] . In this assay Renilla luciferase 8 (Rluc8), used as energy donor, is located on the Gaq subunit, while GFP 10 , the energy acceptor, is located on the Gc subunit of the G protein. Thus, a decrease of the BRET signal triggered by agonist-induced receptor activation is indicative of an opening of the Ga-Gbc interface, reflecting the initial event of Gq protein activation [32, 43] . Thus, after setting the optimal transfection conditions to assure the same level of basal BRET signal for WT and different TPa mutants [32, 36] , concentration-response curves of the stable agonist U46619 have been performed in HEK293T cells expressing equal amount of WT and mutant TPa receptors. As it is clear from Fig. 11A , the U46619 curve obtained with the DDM mutant shows a significant (p < 0.01) decrease in potency with more than a fivefold rightward shift with respect to the curves obtained with the WT TPa receptor (Table 4) . Similar results were obtained with the N42S and W29C variants (Fig. 11B) . Comparison of EC 50 for WT and W29C reveals a perfect agreement with those obtained from the analysis of total IP dose-response curves (see Table 2 and Fig. 10A ). Statistical comparison of potencies provided a significant difference between parameters obtained with WT and the different TPa variants, thus demonstrating a reduced ''efficiency" in G protein activation by the mutated proteins (Table 4) .
Discussion
Despite the intense effort devoted to demonstrate the mechanism(s) by which GPCRs form complexes with each other, the physiological relevance of this phenomenon still remains elusive [11, 15] [16]. Hetero-dimerization has been shown to be an absolute requirement for the activity of some Class C GPCRs [13, 14] and the cell-surface delivery of other GPCRs [44, 45] . The process can also be regarded as a way of creating a receptor complex endowed with unique signaling features in response to the binding of specific ligands [46, 47] . A more difficult issue to characterize is the role of receptor homo-dimerization in terms of receptor activation and function. In order to address this question we characterized the pharmacological activity of the human TP receptor, containing either artificial (DDM TP) [26] or naturally occurring (W29C and N42S) [23, 24] mutations in TM1, impaired in its ability to spontaneously form receptor dimers.
The main key finding of the present study comes from the detailed pharmacological characterization of the DDM TP receptor using a combination of antagonists and full and partial agonists in living cells. Unlike the WT receptor, which spontaneously forms homo-dimers at physiological expression levels, DDM, which is significantly impaired in its ability to form dimers, displays a significant reduction in agonist potency in comparison to the WT. Despite a reduction in agonist potency, the WT and DDM receptors have indistinguishable overall and active conformations as assessed by antagonist and agonist ligand-binding studies and possess similar abilities to bind and induce G q -mediated signaling. However, the DDM receptor clearly shows a reduced 'efficiency' in G protein activation. Thus, TM1 appears to be an important region contributing to the normal function of the TPa receptor in vitro. To support these findings two recent studies examining naturally occurring variants in the TPa receptor, W29C and N42S identified in two patients with bleeding disorders, demonstrated that platelets from these patients exhibited a decrease in TP receptor-stimulated activation. We now demonstrate that both W29C and N42S TPa receptor variants are impaired in their ability to dimerize in a recombinant system, and with a partial reduction also apparent in platelets from these patients. Strikingly, one of these naturally occurring mutations (W29C) exactly matches, and the other (N42S) is just one residue upstream of two out of the eight residues mutated in our artificial DDM. Thus, we suggest that a single mutation in TM1 might be sufficient to impair homo-dimer formation, and may in part be responsible for the observed decrease in TP receptor functionality observed in vivo.
Although DDM is expressed at the cell surface at physiologically relevant levels it is drastically impaired in its tendency to form homo-dimers over a range of different expression levels, as demonstrated by western blotting and acceptor photobleaching FRET analysis. Ligand-binding studies with the TP receptor antagonist SQ29,548 confirm normal protein folding, and suggest a conserved overall protein conformation, as also previously postulated by molecular dynamic simulations [26] .
In functional assays DDM signaling was significantly impaired versus WT with a significant rightward shift in agonist-potency across a panel of full and partial TP receptor agonists. In agreement with this loss of agonist activity, two structurally different antagonists demonstrated an apparent increase in their potency. Most importantly, despite their reduced potency in promoting DDM activation, all the ligands investigated retained their respective pharmacological profiles as either full or partial agonists. In addition, the basal activity of DDM is similar to that of WT and not affected by increased expression of its cognate G protein, a further validation of TP 'resistance' to CA [31, 34, 36] .
Importantly, co-transfection of the WT TP receptor with a truncated form of TP coding only for the N terminal and TM1 regions produced a pharmacological profile similar to that of the DDM. Because TPtrunc is able to dimerize with WT receptor, its coexpression very likely impairs WT-WT TP dimer formation, forcing TP receptor into a monomeric form. This, in turn, suggests that the monomeric form of TP, as for many other GPCRs, is able to signal, and that the pharmacological profile observed for the DDM might indeed be due to its monomeric state and not to merely the presence of mutations.
In addition, the phenotype described for this 'artificial' DDM matches the phenotypes of the W29C and N42S TPa natural variants [23, 24] . In these studies we suggested that reduced TP receptor surface expression seen in the W29C patient reduced TP receptor-stimulated platelet aggregation. We now speculate that in addition to this reduction in surface expression, since both the W29C and N42S are impaired in the dimerization with WT, the heterozygous patients may also display a shift in the normal equilibrium from TPa homo-dimers to monomers with a consequent overall decrease in agonist potency. Western blotting of patient platelets TPa reveals receptor in monomeric, dimeric, and Results are indicated as BRET ligand effect that has been calculated as the differences in the BRET signal measured in the presence and the absence of the agonist, and are expressed as the mean value ± SE of at least three independent determinations. Values for EC 50 0 s and significant differences from WT are shown in Table 4 . higher-order oligomeric forms in agreement with previously published results [25] . These blots suggested that there maybe a modest reduction in TPa oligomer although it should be noted that both patients are heterozygous for each variant and therefore will also express WT TP receptor. The presence of WT TP receptor is likely to mask our ability to see a statistically significant reduction in dimer formation. Intriguingly, each of these variants shows comparable levels of maximal receptor responsiveness to agonists when compared to WT, but have reduced potency in second messenger production [23, 24] , as it is the case for the artificial DDM. It is therefore tempting to speculate that the impairment in dimer formation might represent a crucial molecular mechanism of the decreased platelet response to TP agonists in vivo.
In an attempt to clarify whether the change in agonist potency might arise from a change in the ligand-binding pocket and/or in an allosteric effect within the protomers of the TPa homo-dimer [48] , we analyzed the agonist binding profile of a series of compounds endowed with different intrinsic activities. All the tested agonists displayed equal binding affinities for the DDM and WT receptors, thus indicating that the agonist-induced active state of the monomeric and dimeric proteins are similar, and supporting the absence of any allosteric modulation across protomers of the TPa homo-dimer at the level of the binding pocket. Notably, the DDM retains high affinity agonist binding that is indicative of a normal coupling with the cognate G proteins. Thus, differences able to explain a reduced potency of agonists in DDM activation must be sought downstream of the TP receptor itself, likely at the G protein level. Indeed, direct analysis of G protein activation by a BRET 2 -based technique clearly demonstrates a reduced efficiency in G protein activation for our artificial DDM as well as for the N42S and, especially, W29C variants.
Collectively, all these observations strongly support the notion that reduced agonist potencies demonstrated by the DDM in second messenger production do not arise from a change in the receptor state, i.e. by a variation in agonist-induced conformation, or in the receptor ability to recognize pharmacodynamically different agonists, or in its ability to interact with G proteins. Rather, these data are suggestive of a reduced signaling strength, due to a reduced efficiency in G protein activation.
While we recognize that we cannot completely rule out the possibility that the differences observed in our DDM might depend upon the presence of the mutations alone, the fact that a single mutation (W29C or N42S) or dimerization with a truncated and silent form of the receptor closely matches the pharmacology of our DDM, convincingly indicates that the particular pharmacological profile observed with our TP mutants may be the result of an impairment of dimer/oligomer formation.
In respect to this, contrasting data are emerging on G protein activation by different dimeric GPCRs. Some data support a model of a higher efficiency of G protein activation in dimers/oligomers [29, 49, 50] , while others demonstrate a similar degree of activation [6, 7] , or even a reduced G protein coupling efficiency by dimeric ensembles [9, 10] . While it is possible that different receptors might simply behave differently from another, it is also true that the same receptor seems to behave differently in different experimental conditions as shown with rhodopsin isolated by filtration techniques [29] versus expression in a phospholipid bilayer [7] . To our knowledge, our functional results are the first to be obtained with a dimeric and a monomeric form of a Class A GPCR expressed in living cells that is not artificially purified/reconstituted. More data on other receptor systems will certainly come in the near future to clarify this issue, as it has been recently the case for the glucagon-like peptide-1 receptor, where homo-dimer formation seems important for the control of signal bias [51] .
Finally, while the stoichiometry of the receptor-G protein unit still remains an open question, a number of studies favor a 2:1 stoichiometry, corroborating the hetero-pentameric structure of two protomers binding one heterotrimeric G protein [50, [52] [53] [54] [55] . A number of biochemical studies suggest the involvement of several distinct G protein regions in receptor interaction [56] , both on the a [57, 58] , as well as on the c-subunit [59, 60] . While the C-terminal sites on the a-subunit have been confirmed by crystallization to interact with opsin/metarhodopsin [61] and b 2 -AR [62] , unexpectedly, no direct interaction between b 2 -AR and Gb-or Gc-subunits has been detected [62] . Indeed biochemical studies suggest that b 2 -AR exists as a dimer in living cells [63] and that the C-terminal of Ga and of Gc are further apart in the G protein heterotrimer than the width of a monomeric GPCR [64] . Thus, the 2:1 stoichiometry is consistent with multiple contact sites of the G protein with two different protomers [65, 66] , whereas the heterotrimer appears necessary for efficient coupling to a GPCR [67] . In light of our data and of this 'double docking' model described above we can speculate that, when a secondary site of contact is available due to the presence of a homo-dimer, a stronger coupling with the cognate G protein is favored, hence more efficient signaling is then possible. Indeed, the presence of transducin has been shown to stabilize the dimeric conformation of rhodopsin, while the presence of synthetic peptides that disrupt rhodopsin dimerization, similar to our truncated TP receptor construct, inhibited such stabilization [41] .
In conclusion, our data propose that TPa receptor dimer formation favors a more efficient signaling complex, increasing agonist potency. This augmented ability is very likely the result of a more efficient G protein activation. Given that TP monomers and homodimers are, presumably, in equilibrium at steady state [68, 69] , it is possible that when a single TPa protomer makes a complex with a TPb [25, 26] or IP protomer [27] there would be a shift in the equilibrium from TPa homo-dimers to monomers with a consequent overall decrease in agonist potency, which may be important in thrombosis-related diseases. In this respect, the impairment of W29C and N42S to form dimers with WT receptor may represent one molecular mechanism through which platelet TP receptor dysfunction affects the patient(s) carrying these mutations.
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